What Are the Signs of End-Stage Pancreatic Cancer?

End-stage pancreatic cancer produces a recognizable cluster of signs that reflect the disease spreading beyond the pancreas and overwhelming multiple organ systems. Severe abdominal pain, rapid weight loss, jaundice, fluid buildup in the abdomen, and profound fatigue are among the most common. These signs often overlap and accelerate together, making the final weeks and months distinct from earlier stages in ways that patients, families, and care teams can usually identify. The picture is grimmer than for most cancers: when pancreatic cancer has spread widely, median survival is measured in months, not years.¹

Pain That Becomes Constant and Hard to Control

Pain is the symptom most closely associated with advanced pancreatic cancer, and it tends to worsen as the disease progresses. Roughly half to seven in ten patients experience severe pain at some point during the illness.² In end-stage disease, the pain usually settles deep in the upper abdomen and radiates through to the back. This happens because the tumor presses on or invades the celiac plexus, a dense web of nerves behind the pancreas that relays sensation from most of the upper abdomen. As the cancer grows into surrounding tissues, the pain shifts from intermittent to constant and often becomes difficult to manage with standard oral medications alone.

The severity can be disabling. Patients frequently describe it as a deep, gnawing ache that intensifies after eating or when lying flat, sometimes forcing them to curl forward for relief. At this stage, opioid doses often need to climb, which introduces its own problems: drowsiness, constipation, nausea, and confusion. This escalating cycle of pain and side effects is one of the main reasons families notice a sharp decline in quality of life near the end.

Jaundice and Bile Duct Obstruction

Yellowing of the skin and eyes is one of the most visible signs of advanced pancreatic cancer, especially when the tumor is in the head of the pancreas. The tumor blocks the common bile duct, trapping bile that normally drains into the small intestine. As bilirubin backs up into the bloodstream, the skin and whites of the eyes turn yellow, urine darkens, and stools become pale or clay-colored. Intense itching often accompanies the jaundice and can be maddening on its own.

In patients whose cancer cannot be surgically removed, biliary obstruction often recurs or worsens as the disease progresses. Self-expanding metal stents placed through an endoscope can reopen the blocked duct, and the procedure succeeds in over 90 percent of cases.³ One study of a partially covered nitinol stent found that about 62 percent of patients were free of obstructive symptoms at six months, with bilirubin levels dropping by roughly three-quarters compared to baseline.⁴ These stents do not treat the cancer itself, but relieving the obstruction can make a real difference in comfort and sometimes allows chemotherapy to resume when it had to be paused because of high bilirubin.

Nausea, Vomiting, and Bowel Obstruction

As the tumor grows, it can press on or invade the duodenum, the first section of the small intestine that sits right next to the pancreas. This obstruction makes it difficult or impossible for food to pass through, producing persistent nausea, vomiting shortly after eating, bloating, and a feeling of fullness after only a few bites. In cancers arising from the uncinate process of the pancreas, the obstruction sometimes occurs lower down, in the third portion of the duodenum, which can be harder to reach and stent.⁵

Bowel obstruction from peritoneal spread is a separate and ominous development. When cancer seeds itself across the lining of the abdominal cavity, it can kink or block multiple loops of the intestine simultaneously. In one study of patients who died from pancreatic cancer, peritoneal carcinomatosis causing bowel obstruction or large-volume fluid buildup accounted for roughly a quarter of all cancer-related deaths.⁶ At this point, eating becomes nearly impossible, and nutrition shifts to comfort-focused care rather than any attempt to sustain caloric intake.

Ascites and Abdominal Swelling

Malignant ascites, the accumulation of fluid in the abdominal cavity driven by the cancer itself, often signals the terminal phase of pancreatic cancer.⁷ The abdomen swells, sometimes dramatically, creating pressure that makes breathing harder, reduces appetite further, and adds to pain. The fluid can be drained with a needle (a procedure called paracentesis), which offers temporary relief, but it typically reaccumulates within days or weeks.

In a study of over 580 patients with metastatic pancreatic cancer, about one in five developed ascites, usually appearing around nine months after the diagnosis of metastatic disease. Once ascites developed, the outlook was stark: median survival afterward was just one month, and the occurrence carried roughly a ninefold increased risk of death.⁸ This makes the onset of ascites one of the clearest clinical markers that time is very short.

Severe Weight Loss and Muscle Wasting

Cancer cachexia, a syndrome of involuntary weight loss and skeletal muscle breakdown, is especially aggressive in pancreatic cancer. Patients often lose 10 percent or more of their body weight before the end-stage, and in the final weeks the wasting can become startling. Unlike simple malnutrition, cachexia cannot be reversed just by eating more. The cancer itself drives the process by releasing inflammatory molecules and tumor-derived factors that push the body into a state of breakdown.

Research has identified specific mechanisms through which pancreatic tumors attack muscle. Pancreatic cancer cells release a protein called PAUF that triggers rapid muscle protein loss.⁹ More broadly, cytokines released through the interplay between tumor and host cells drive appetite loss, an elevated metabolic rate, and direct muscle breakdown and cell death.¹⁰ This means the wasting is not simply a consequence of not eating; even patients receiving supplemental nutrition continue to lose muscle mass. For families watching this happen, it can be one of the most distressing visible signs that the disease is advancing.

Sarcopenia, or severe muscle depletion, has been identified as an independent predictor of shorter survival in pancreatic cancer patients, carrying more than a threefold increase in the risk of death in some analyses.¹¹ Doctors sometimes measure muscle mass on CT scans as part of assessing a patient’s overall trajectory.

Overwhelming Fatigue

Fatigue in end-stage pancreatic cancer goes well beyond ordinary tiredness. Patients describe it as a bone-deep exhaustion that rest does not fix, and it is often rated as the most disruptive symptom after pain. In a qualitative study of patients with advanced pancreatic cancer and their caregivers, fatigue was among the ten most frequently reported symptom categories, and patients described some of these symptoms as severe, life-changing, and highly distressing.¹² The fatigue stems from several converging forces: the metabolic havoc of cachexia, anemia, poor nutrition, the side effects of opioids and other medications, and the sheer energy demand the cancer places on the body.

In practical terms, fatigue progressively narrows a patient’s world. Activities that were manageable weeks earlier, like getting out of bed, walking to the bathroom, or sitting up to eat, become exhausting ordeals. A noticeable drop in functional status over days rather than weeks is a common signal that the disease is entering its final phase. Clinicians track this through performance status scales, and a sharp decline in that score is one of the most reliable prognostic markers.¹³

Blood Clots

Pancreatic cancer carries one of the highest rates of venous thromboembolism among all cancers.¹⁴ The tumor pushes the blood into a hypercoagulable state through multiple pathways, including genetic changes in the cancer cells themselves, the release of clotting-promoting factors, mucin production that activates platelets, and the inflammatory chemicals the tumor generates.¹⁵

Clots typically show up as deep vein thrombosis in the legs, causing sudden swelling, warmth, and pain in one calf or thigh. If a clot breaks loose and travels to the lungs (pulmonary embolism), it causes sudden shortness of breath, chest pain, and can be immediately life-threatening. In end-stage disease, patients may develop clots even while on blood thinners. Unexplained blood clots in someone without other risk factors are sometimes the very first clue that pancreatic cancer is present, a phenomenon described nearly 150 years ago and still known as Trousseau’s syndrome.

Confusion, Delirium, and Cognitive Changes

Mental status changes in end-stage pancreatic cancer can appear gradually or strike suddenly. Patients may become confused about where they are, have difficulty following conversations, grow agitated or unusually drowsy, or experience hallucinations. This is clinically referred to as delirium, and it has multiple potential triggers at this stage: liver failure from metastases impairing the organ’s ability to clear toxins, medications (especially opioids), dehydration, infection, and electrolyte imbalances.

Delirium is a serious marker of decline. A nationwide study of nearly 150,000 hospitalized pancreatic cancer patients found that those with concurrent delirium had nearly four times the odds of dying in the hospital compared to those without it. These patients also faced higher rates of acute kidney injury, sepsis, respiratory failure, and ICU admission.¹⁶ For families, the sudden onset of confusion in a loved one who was still mentally clear days earlier can be alarming and is often the moment when the reality of the situation becomes impossible to avoid.

How the Final Days Look

In the last days of life, certain physical signs become apparent that indicate death is imminent. These include changes in breathing patterns such as the so-called “death rattle” (noisy breathing caused by secretions the patient can no longer clear), long pauses between breaths, dropping blood pressure, mottled or cool skin especially on the extremities, and decreasing responsiveness.¹⁷ The person may sleep almost continuously and stop eating or drinking entirely.

These signs are not specific to pancreatic cancer; they occur across advanced cancers and other terminal illnesses. But in pancreatic cancer, the trajectory from clearly declining to actively dying can be compressed. Some patients maintain a reasonable level of function until quite close to the end, then deteriorate over just a few days. The specific cause of death varies. In one study, the most common cause of cancer-related death was distant metastases, with liver failure from hepatic metastases and peritoneal spread together accounting for the vast majority of those deaths.⁶

Managing Pain When Standard Medications Fall Short

Because pain is so central to the end-stage experience, palliative interventions beyond oral opioids deserve attention. A celiac plexus block is a procedure in which a needle is guided to the celiac nerve bundle and an agent is injected to destroy or numb the nerves that carry pain signals from the upper abdomen. A Cochrane review found that this procedure led to modest but meaningful reductions in pain intensity at four and eight weeks, along with significantly lower opioid use compared to medications alone.²

A randomized trial compared neurolytic celiac plexus block against opioid-only management. In the first six weeks, only 14 percent of block patients reported moderate or severe pain, compared to 40 percent of those on opioids alone. The block did not improve overall survival, but it substantially reduced the burden of severe pain during the period it was effective.¹⁸ Current evidence supports the block as highly effective for pancreatic cancer pain specifically, and it is increasingly viewed as a standard part of the palliative toolkit rather than a last resort.¹⁹

The Emotional and Psychological Toll

End-stage pancreatic cancer does not only produce physical symptoms. Anxiety and depression are common and are driven by the severity of the disease, the weight of the symptom burden, financial stress, and the existential fear that comes with a terminal diagnosis.²⁰ Patients who were coping reasonably well earlier in the illness may find that emotional distress escalates sharply as physical decline accelerates, especially when cognitive clarity starts slipping or when they can no longer participate in the activities that gave their days meaning.

Caregivers suffer too. The same qualitative study that cataloged symptom experiences in advanced pancreatic cancer found that caregivers were deeply involved in discussing and managing the full range of symptoms, with some describing the experience as life-changing on their end as well.¹² Grief often begins before death, as families watch the person they know disappear behind the symptoms. Palliative care teams that include social workers, chaplains, and psychologists can address this, but access varies widely depending on where a patient receives care.

When Hospice Enters the Picture

Hospice enrollment has increased substantially for pancreatic cancer patients over the past few decades. In a study of Medicare beneficiaries who died with pancreatic cancer, hospice use rose from about 36 percent in the early 1990s to 67 percent by the mid-2000s. Still, only about a third of hospice users enrolled four weeks or more before death, meaning many patients were referred very late.²¹ Late hospice enrollment is a persistent problem across oncology, but it is particularly unfortunate in pancreatic cancer, where the symptom burden is heavy and the benefits of earlier comfort-focused care are well established.

Part of the reason for late referrals is the compressed timeline of the disease. Patients and families sometimes expect more time than they have, especially if chemotherapy initially seemed to be working. Physicians, too, can be reluctant to shift the conversation from treatment to comfort until the signs of decline are unmistakable. The same study found that ICU admissions and chemotherapy use in the final month of life actually increased over time, suggesting that more aggressive end-of-life care and higher hospice enrollment were rising in parallel, reflecting a tension between doing everything possible and accepting that the disease has won.

Blood Tests That Track the Decline

Several routine blood markers help clinicians assess how quickly the disease is progressing. Elevated CA 19-9, a tumor marker commonly tracked in pancreatic cancer, is associated with worse outcomes when levels are high or rising. But inflammatory markers tell an equally important story. Measures of systemic inflammation, such as the ratio of C-reactive protein to albumin and the neutrophil-to-lymphocyte ratio, have been identified as independent predictors of shorter survival.¹¹ A study of easily obtainable biomarkers in metastatic disease found that these markers predicted death within 90 days even after adjusting for other clinical factors.²²

More experimental work has looked at panels of cytokines, inflammatory proteins measured in the blood, as potential tools for predicting survival more precisely. One model using high-sensitivity CRP and a set of cytokines was able to separate patients into groups with median survival of about four and a half years versus just over a year.²³ These tools are not yet standard in clinical practice, but they underscore how much the body’s inflammatory response reveals about where a patient stands. In everyday terms, when a doctor mentions that a patient’s albumin is dropping or their inflammatory markers are climbing, that is the blood telling the same story as the visible signs: the disease is gaining ground.